Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hamadeh, M. A.
Right arrow Articles by Smith, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hamadeh, M. A.
Right arrow Articles by Smith, L. J.

Chest, Vol 101, 1033-1037, Copyright © 1992 by American College of Chest Physicians

ARTICLES

Sulfasalazine-induced pulmonary disease

MA Hamadeh, J Atkinson and LJ Smith
Department of Medicine, Northwestern University, Chicago.

We report the findings in two patients with sulfasalazine-induced pulmonary disease. The first patient developed pulmonary interstitial fibrosis after more than 4 yr of treatment for Crohn's disease. Pulmonary symptoms and chest roentgenographic and pulmonary function abnormalities gradually reversed after stopping the drug. No specific treatment was given. The second patient, who had rheumatoid arthritis without pulmonary disease, received the drug for 1 yr without experiencing any problems. Readministration seven months later resulted in the development of an acute interstitial pulmonary disease. Discontinuing the drug and treatment with corticosteroids produced rapid improvement. We discuss these patients in relation to other reports of sulfasalazine-induced pulmonary toxicity, highlighting their atypical features.


This article has been cited by other articles:


Home page
 Br. J. Radiol.Home page
K Marten, F Fend, H Hautmann, M Kremer, E J Rummeny, and C Engelke
Fatal acute exacerbation of usual interstitial pneumonia in ulcerative colitis
Br. J. Radiol., August 1, 2005; 78(932): 762 - 766.
[Abstract] [Full Text] [PDF]

Home page
 ImagingHome page
N J Screaton and T Koh
Emphysema and smoking-related lung diseases
Imaging, October 1, 2004; 16(1): 50 - 60.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S.D. Parry, C. Barbatzas, E.T. Peel, and J.R. Barton
Sulphasalazine and lung toxicity
Eur. Respir. J., April 1, 2002; 19(4): 756 - 764.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J.-F. Cordier
Rare diseases bullet 8: Organising pneumonia
Thorax, April 1, 2000; 55(4): 318 - 328.
[Full Text]

Home page
 NEJMHome page
D. S. Lazarus and E. J. Mark
Case 12-1993- A 44-Year-Old Man with Pulmonary Disease and Proctitis
N. Engl. J. Med., March 25, 1993; 328(12): 869 - 876.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Chest Physicians.